Insider · CIK 0001725595
Joel Lewis
Files at GALT (GALECTIN THERAPEUTICS INC). First filing Dec 26, 2024, latest Jan 6, 2026.
Joel Lewis files SEC Form 4 as CEO, president and director at GALT (GALECTIN THERAPEUTICS INC). Since Dec 26, 2024, Joel Lewis has reported 0 open-market buys worth $0 and 8 open-market sells worth $759k, the latest filed on Jan 6, 2026.
A track record needs three past buys with six months of prices behind them; Joel Lewis has 0, so none is measured yet.
The newest scored trade: sold $321k of GALT on Jan 2, 2026, filed Jan 6, 2026, scored 19 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $621k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GALT: GALECTIN THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | GALECTIN THERAPEUTICS INC | $321k 84,000 shares | -9% | +268% from low-38% from high | |
| 12Weak | GALECTIN THERAPEUTICS INC | $55k 7,829 shares | -1% | +670% from low-1% from high | |
| 16Weak | GALECTIN THERAPEUTICS INC | $136k 22,463 shares | -3% | +614% from low0% from high | |
| 5Weak | GALECTIN THERAPEUTICS INC | $11k 1,867 shares | -0% | +519% from low-13% from high | |
| 5Weak | GALECTIN THERAPEUTICS INC | $1,200 200 shares | -0% | +570% from low-6% from high | |
| 15Weak | GALECTIN THERAPEUTICS INC | $95k 15,720 shares | -2% | +614% from low0% from high | |
| 7Weak | GALECTIN THERAPEUTICS INC | $89k 14,000 shares | -2% | +539% from low-10% from high | |
| 12Weak | GALECTIN THERAPEUTICS INC | $50k 56,000 shares | -6% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | 40,000 0.06% of outstanding | $282k | Dec 17, 2025 | $244k |
| Sep 12, 2025 | GALT GALECTIN THERAPEUTICS INC | 54,250 0.08% of outstanding | $345k | Sep 12, 2025 | none |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | 56,000 0.09% of outstanding | $58k | Dec 23, 2024 | none |
Transactions
Every row this insider has filed, 39 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 22, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative10b5-1 | +84,000 | $0.00 | $0 | 65,000 | Jan 21, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Restricted Stock Unitderivative10b5-1 | +120,000 | $0.00 | $0 | 100,000 | Jan 21, 2026 |
| Jan 5, 2026 | GALT GALECTIN THERAPEUTICS INC | Other Common Stock10b5-1 | -56,332 | $3.88 | $219k | 776,260 | Jan 13, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +84,000 | $0.00 | $0 | 916,592 | Jan 6, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -18,571 | $4.20 | $78k | 898,021 | Jan 6, 2026 |
| Jan 5, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -27,731 | $3.91 | $108k | 870,290 | Jan 6, 2026 |
| Jan 6, 2026 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -37,698 | $3.58 | $135k | 832,592 | Jan 6, 2026 |
| Jan 2, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -84,000 | $0.00 | $0 | 0 | Jan 6, 2026 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +7,829 | $2.86 | $22k | 840,421 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -7,829 | $7.06 | $55k | 832,592 | Dec 19, 2025 |
| Dec 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -7,829 | $0.00 | $0 | 32,171 | Dec 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +15,680 | $2.39 | $37k | 848,272 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -15,680 | $6.04 | $95k | 832,592 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +6,783 | $2.39 | $16k | 839,375 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -6,783 | $6.15 | $42k | 832,592 | Nov 19, 2025 |
| Nov 17, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -15,680 | $0.00 | $0 | 6,783 | Nov 19, 2025 |
| Nov 18, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -6,783 | $0.00 | $0 | 0 | Nov 19, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +1,867 | $2.39 | $4,462 | 834,459 | Nov 12, 2025 |
| Nov 10, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -1,867 | $6.03 | $11k | 832,592 | Nov 12, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -1,867 | $0.00 | $0 | 22,363 | Nov 12, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +200 | $2.39 | $478 | 832,792 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -200 | $6.00 | $1,200 | 832,592 | Nov 7, 2025 |
| Nov 5, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 24,230 | Nov 7, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +1,300 | $2.39 | $3,107 | 833,892 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -1,300 | $6.01 | $7,813 | 832,592 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +14,420 | $2.39 | $34k | 847,012 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -14,420 | $6.07 | $88k | 832,592 | Nov 5, 2025 |
| Nov 3, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -1,300 | $0.00 | $0 | 38,950 | Nov 5, 2025 |
| Nov 4, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -14,420 | $0.00 | $0 | 24,530 | Nov 5, 2025 |
| Sep 12, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +14,000 | $2.39 | $33k | 846,592 | Sep 15, 2025 |
| Sep 12, 2025 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -14,000 | $6.36 | $89k | 832,592 | Sep 15, 2025 |
| Sep 12, 2025 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Stock option (right to buy)derivative10b5-1 | -14,000 | $2.39 | $33k | 40,250 | Sep 15, 2025 |
| Mar 3, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Common Stock | -56,420 | $1.57 | $89k | 832,592 | Mar 5, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock Option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 27, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Restricted Stock Unitderivative | +84,000 | $0.00 | $0 | 84,000 | Jan 27, 2025 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stock10b5-1 | +56,000 | $0.00 | $0 | 953,012 | Dec 26, 2024 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | SOpen-market sale Common Stock10b5-1 | -56,000 | $0.89 | $50k | 897,012 | Dec 26, 2024 |
| Dec 23, 2024 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Restricted Stock Unitsderivative10b5-1 | +56,000 | $0.00 | $0 | 0 | Dec 26, 2024 |
Questions about Joel Lewis
Answered from the filings on this page, as of the latest one.
Is Joel Lewis buying or selling?
In the last 12 months Joel Lewis reported 0 open-market buys worth $0 and 6 open-market sells worth $621k on SEC Form 4; the latest was sold $321k of GALT on Jan 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Joel Lewis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joel Lewis has 0.
Where does Joel Lewis file Form 4?
Joel Lewis has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.